CoChat

Ocular Gene Therapy: A Literature Review with Special Focus on Immune and Inflammatory Responses

Open access

The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index; 74 of the 186 sources its claims cite were checked for support.

Abstract

Gene therapy has emerged as a research topic of choice in recent years. The eye in particular is one of few organs of the body for which gene therapy has received Food and Drug Administration approval, and it remains a field of great interest for gene therapy development. However, its associated immune and inflammatory reactions may render the treatment ineffective or harmful, which are of particular concern for the eyes due to their susceptibility to inflammation. The severity of immune and inflammatory reactions depends on the choice of vector and its route of administration. Furthermore, most preclinical and clinical studies have shown that the dose of vectors is correlated with the degree of humoral response and ocular inflammation. The route of administration directly impacts the degree of immune and inflammatory reaction. Subretinal delivery produces a weaker humoral response than the intravitreal route. However, some studies have demonstrated that the subretinal delivery induces a stronger inflammatory reaction. On the other hand, several instances of vision loss due to severe late onset intraocular inflammation were reported in a clinical trial involving intravitreal delivery of viral vectors. When compared with the intravitreal route, suprachoroidal gene delivery has been shown to produce weaker humoral response. However, unlike the subretinal space, the suprachoroidal space is not known to have immune privilege status. Inflammatory reactions following ocular gene therapy are typically mild and most clinical and preclinical studies have shown that they can be controlled with topical, local or systemic steroids. However, severe inflammatory responses may occur and require aggressive management to avoid permanent vision loss. Further investigations are required to elucidate and expand our knowledge of inflammatory reactions, and their optimal management, following ocular gene therapy.

Overview

CoChat Summary

TL;DR

This review summarizes ocular gene therapy vectors, delivery routes, and the immune/inflammatory responses that can limit efficacy or cause harm. It concludes that reactions are usually mild and steroid-responsive, but high-dose intravitreal therapy can cause late-onset sight-threatening inflammation.

Key findings

  • Route shapes immune response: subretinal delivery produces a weaker humoral response than intravitreal delivery, while some studies found subretinal delivery induces stronger inflammatory reactions; suprachoroidal delivery has a weaker humoral response than intravitreal but lacks known immune privilege. In the INFINITY trial of intravitreal AAV for diabetic macular edema, patients received high virus dose (N=12), lower virus dose (N=13), or aflibercept (N=9); 3 high-dose patients developed late-onset significant inflammation including panuveitis with hypotony, none in the low-dose or aflibercept groups did, and 2 high-dose patients required mycophenolate.
  • Vector dose correlates with inflammation in several trials: Cukras et al. gave AAV8 RS1 intravitreally at 1×10⁹, 1×10¹⁰, and 1×10¹¹ viral particles/eye to nine XLRS patients and found dose-dependent ocular inflammation and dose-dependent serum anti-AAV8 antibodies, with inflammation resolving on oral/topical corticosteroids. Le Meur et al. gave subretinal AAV2 in RPE65-LCA at low (1.22–2×10¹⁰) or high (3.27–4.8×10¹⁰) viral genomes to nine patients; mild anterior chamber protein flare occurred in only 3 patients at the highest dose and resolved after 14 days with local/systemic steroids.
  • The FDA-approved voretigene neparvovec trial enrolled 29 pediatric patients older than 3 years with LCA and visual acuity of 20/60 or less, randomized 2:1 to intervention or control; it improved functional vision, had no treatment-related serious adverse events, and mild ocular inflammation occurred in only 2 patients (10%) and resolved.
  • AAV seroprevalence and vector constituents matter: about 70% of the normal population has preexisting antibodies against AAV2 versus about 38% against AAV8; antiviral antibodies correlate with minimal or absent gene expression. Timmers et al. found anterior segment inflammation depended on the viral genome, empty capsids did not induce anterior reaction, both full particles and empty capsids induced vitreal inflammation, and antibodies were generated regardless of genome presence.

Methods

  • Design: narrative literature review focused on ocular gene therapy and associated immune/inflammatory responses.
  • Data: synthesis of preclinical and clinical studies and clinical trials covering viral vectors (adenovirus, AAV, lentivirus), non-viral vectors, ocular disease applications, delivery routes (intravitreal, subretinal, suprachoroidal, electrotransfection), dose/constituent effects, and inflammation management.
  • Analysis: qualitative synthesis with referenced tables/figures (Table 1, Table 2, Figure 1); no systematic search strategy, inclusion criteria, or quantitative meta-analysis is described in the provided text.

Limitations

  • Paper-stated: further investigations are required to elucidate inflammatory reactions and their optimal management after ocular gene therapy; suprachoroidal delivery needs more study regarding its immune/inflammatory profile; no published data exist on electrotransfection safety in human eyes; small patient numbers may explain why some studies did not detect dose-dependent ocular inflammation; Yiu et al.’s suprachoroidal comparison had a small sample size and was performed in non-human primates.
  • Evident from the text: as a narrative review, it does not report a systematic search strategy, formal inclusion/exclusion criteria, risk-of-bias assessment, or quantitative synthesis.
  • Evident from the text: evidence is drawn from heterogeneous preclinical and clinical studies, including animal and non-human primate models, with varying vectors, doses, routes, endpoints, and underlying diseases, which limits generalizability.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.2147/opth.s364200

Cites

102 of 102 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Images showing different methods of intraocular gene delivery: (A) intravitreal, (B) suprachoroidal, and (C) subretinal.
Figure 1 Images showing different methods of intraocular gene delivery: (A) intravitreal, (B) suprachoroidal, and (C) subretinal.CC BY-NC · PubMed Central

Verification

Claims the paper makes

61 Valid · 11 Not valid · 51 Not checked · 27 Own results and interpretations

92 more claims · 40 with their cited sources checked

Create a free account to see all 150 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 48
  • Probably not a substantial claim. 7

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 102 references

Research works printed but not linked: 7

  1. Pepose, 1994, Invest Ophthalmol Vis Sci, 35, 2662
  2. Jiang, 1991, Invest Ophthalmol Vis Sci, 32, 224
  3. Atherton, 1987, Invest Ophthalmol Vis Sci, 28, 859
  4. Li, 2008, Mol Vis, 14, 1760
  5. Wykoff Obotii CC. Intravitreal gene therapy for diabetic macular edema with ADVM-022: first-time data presentation of prospective, randomized phase 2 INFINITY trial [Conference presentation]. American Society of Retina Specialists Annual Scientific Meeting; October 8-12, 2021; 2021; San Antonio, Texas, USA.
  6. Dante Pieramici O. ADVM-022 intravitreal gene therapy for neovascular AMD: phase 1 OPTIC study [Conference presentation]. American Society of Retina Specialists Annual Scientific Meeting; October 8-12, 2021; 2021; San Antonio, Texas, USA.
  7. Bucher, 2021, Prog Retin Eye Res, 83, 100915, 10.1016/j.preteyeres.2020.100915 · DOI · Paper page

Cited by

Metadata

Authors
Ghoraba, H. H., Akhavanrezayat, A., Karaca, I., Yavari, N., Lajevardi, S., Hwang, J., Regenold, J., Matsumiya, W., Pham, B., Zaidi, M., Mobasserian, A., DongChau, A. T., Or, C., Yasar, C., Mishra, K., Do, D., & Nguyen, Q. D.
Affiliations
Stanford University (US)
Corresponding author
  • Ghoraba, Hashem H
  • Akhavanrezayat, Amir
  • Karaca, Irmak
  • Yavari, Negin
  • Lajevardi, Sherin
  • Hwang, Jaclyn
  • Regenold, Jonathan
  • Matsumiya, Wataru
  • Pham, Brandon
  • Zaidi, Moosa
  • Mobasserian, Azadeh
  • DongChau, Anthony Toan
  • Mishra, Kapil
  • Nguyen, Quan Dong
Venue
Clinical Ophthalmology
Published
2022-06
Volume
Volume 16
Pages
1753-1771
ISSN
  • 1177-5467 (ISSN-L)
  • 1177-5483
OpenAlex
W4281606199
Cited by
76
References
102
Citations by year
2026: 20 · 2025: 19 · 2024: 20 · 2023: 13 · 2022: 4
FWCI
1.46
Type
journal article
Language
en
Open access
Locations
  • Clinical ophthalmology (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Funders
National Eye Institute (P30EY026877)
Topics
  • Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
Keywords
ocular gene therapy, immune response, ocular inflammation, viral vectors, route of administration, subretinal delivery, intravitreal delivery, humoral immune response, intraocular inflammation, vision loss, immune privilege

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.